Enhanced immune response with baculovirus-expressed BoHV-1 glycoprotein D in vaccine development.

Bovine herpesvirus 1 (BoHV-1), a significant pathogen in the alpha-herpesvirus subfamily, primarily infects cattle and causes the upper respiratory disease known as infectious bovine rhinotracheitis (IBR). In silico studies evaluated the BoHV-1 D protein to be non-allergenic, non-toxic, and highly antigenic, highlighting its potential as an antigen for vaccine development. Therefore, this study aimed to evaluate the efficacy of a subunit vaccine using the ectodomain of glycoprotein D (gD 34–380) as an antigen. The truncated gD was successfully cloned and expressed in both Escherichia coli (E. coli , termed EgD) and baculovirus (termed BgD) systems, with expected molecular weights of 65 kDa and 50 kDa, respectively. For the vaccine formulation, the gD proteins were used either alone or in combination with in-house inactivated BoHV-1. Vaccination of mice and bovines showed that baculovirus-expressed gD 34–380 accelerated the antibody response. Moreover, the BgD-vaccinated group also showed significantly higher neutralizing antibody levels against BoHV-1 than the control group (p<0.0001). In conclusion, our study found that BgD from BoHV-1 can increase the immune response and enhance vaccine efficacy. • The immunogenicity of modified glycoprotein D including the ectodomain against BoHV-1 was evaluated. • Baculovirus-expressed glycoprotein D retained the immunological properties of authentic gD. • Baculovirus-expressed glycoprotein D induced neutralizing antibody against BoHV-1 in both mice and bovine. [ABSTRACT FROM AUTHOR]